chrisvoncsefalvay/vaers-outcomes huggingface dataset:
she got the last dose of the COVID vaccine on the 5th, then diagnosed with COVID on the 9th; she got the last dose of the COVID vaccine on the 5th, then diagnosed with COVID on the 9th; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 67-year-old female patient received BNT162b2 (BNT162B2), on 09Feb2021 as dose 1, single (Lot number: EN6201), on 02Mar2021 as dose 2, single (Lot number: EN6198), on 30Aug2021 as dose 3 (booster), single (Lot number: EW0185) and on 05Apr2022 as dose 4 (booster), single (Lot number: FM0698) at the age of 67 years for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset 09Apr2022, outcome "unknown" and all described as "she got the last dose of the COVID vaccine on the 5th, then diagnosed with COVID on the 9th". Therapeutic measures were taken as a result of suspected covid-19.
woke from nap 4/4/99 w/rash (red, gritty to touch), on abd, fever 101-102.0 & vomiting, temp to 103 & rash spread to face back & legs;to ER lab u/a & CXR;dx bronchitis;rash rxn;severe cough;
blister at injection site; This case was reported by a consumer via interactive digital media and described the occurrence of injection site blisters in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 7th October 2020, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site blisters. On an unknown date, the outcome of the injection site blisters was unknown.   It was unknown if the reporter considered the injection site blisters to be related to Shingrix.  Additional details were reporter as follows: The age at vaccination was not reported. The age group was not reported but it was selected as an adult as per a vaccine indication. The patient received a Shingrix injection at pharmacy on Wednesday even had a blister at injection site. No further information was provided. The reporter consented to follow up.
FULL BODY RASH; This spontaneous report received from a consumer via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 11-MAR-2021 for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On 14-MAR-2021, the subject experienced full body rash. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of full body rash was not reported. This report was non-serious.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 23-JUN-2014 the patient was vaccinated with a dose of improperly stored RECOMBIVAX HB (strength reported as 2.5/0.5, lot#, dose, route, indication not reported). Concomitant therapy was not reported. No Adverse symptoms were reported. This is one of several reports from the same reporter. Additional information has been requested.
Within minutes of receiving the vaccine, I felt tingling in my left arm at the shot injection site. About 20 mins later, I felt tingling and numbness in my upper lip as well as just above my lip. Consulted with the pharmacist who administered the shot as well as an on-line nurse about adverse side effect. I was instructed to take Benedryl, which I did (37.5 mg). It didn?t do anything to address the tingling. It has been four plus days since the vaccination and the right side of my upper lip feels swollen.
The patient reports she had progressive shortness of breath for the past month, after she received her second dose of COVID vaccine.  She presented to hospital on 5/22/21 with pulmonary embolism.
This case was reported by a healthcare professional and described the occurrence of injection site pain in an adult subject of unspecified gender who was vaccinated with Flulaval (GlaxoSmithKline) for prophylaxis.  The subject's medical history, concurrent conditions, and concurrent medications were not reported.  No other vaccinations were administered on the date of Flulaval administration.  The subject had received influenza virus vaccine in previous years with no subsequent adverse events.  On an unspecified date the subject received unspecified dose of Flulaval (.5 ml, unknown, unknown arm).  At an unspecified time after vaccination with Flulaval, the subject experienced injection site pain and product complaint.  The subject returned to the clinic for further evaluation.  The healthcare professional considered the events were disabling.  The clinic used a 1 inch, 30 gauge needle to administer the vaccinations.  The office is very concerned about using additional doses of this vaccine and believe there is a quality issue associated with it.  The healthcare professional reported that the injection site pain lasted greater than two weeks.  The outcome of the events was unspecified.  Follow-up information received on 27 November 2007 indicated that the subject was a 39 year old female.  The event of left arm pain was documented and the date of the earliest sign or symptom onset was recorded as 17 October 2007.  The events were reportedly improved and considered by the reporter to be related to treatment with Flulaval.  The events were initially reported as disabling and on follow-up, indicated to not be disabling.  No other details were reported.
Vomiting, diarrhea, general upset stomach. Refusing bottle, stomach pain. Lasted for 4 to five days. Doctor said said keep a close eye on baby and continue to report any new symptoms or concerns. Recommend not having any more doses of this vaccine.
This spontaneous report was received from a medical assistant and refers to an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patients were vaccinated with 5 improperly stored doses of ROTATEQ (dose and frequency were not reported) (lot # M011832 and expiration date 25-JAN-2018) orally for prophylaxis. There were no adverse effects reported. Administered doses of vaccines experienced the temperature excursion between 32 degrees Fahrenheit and 36 degrees Fahrenheit for 9 hours. Data logger was involved. There were no previous excursions reported. Additional information has been requested.
Injection was administered high and far back of upper left arm.  By far the most painful injection I've ever had.  Onset of severe left shoulder pain and limitation of movement of left arm occurred within hours of injection.  I had no prior pain or limits to movement of that arm prior to injection.  For four days, my  left arm was useless and pretty much hung at my side.  I had to lift it with my right hand.   The constant pain and limits to movement eased slightly 5 days post injection but have remained at those levels since and pain increases from late afternoon through evening hours.  I have been unable to sleep on left side since injection.  Ibuprofen, Tylenol, heat and/or ice have brought no relief.
At 3:55pm I started to feel extremely dizzy, shaky, and began sweating profusely. I ate a high protein snack thinking that would help, it didn't. I then began to eat about 8oz of peanut M&M's, 5 mini Snicker bars, 2 frosted sugar cookies, and 14oz of chocolate milk. I sat down, drank 16oz of water. By 4:30pm I was still experiencing the same symptoms so I laid down and took a nap. At 6:00pm I was woken up by the school nurse, checking to see if I was feeling okay. I informed her of my symptoms. At 6:30pm I ate dinner then fell back asleep at 8:00pm I woke up again and was feeling much better.
Facial Numbness, S/P inpatient neuro work-up x 5 days in; DDx: Bilateral Bell's  Palsy
His daughter got COVID-19 2 months ago.; This spontaneous case was reported by a patient family member or friend and describes the occurrence of COVID-19 (His daughter got COVID-19 2 months ago.) in a female patient of an unknown age who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. In 2023, the patient experienced COVID-19 (His daughter got COVID-19 2 months ago.). At the time of the report, COVID-19 (His daughter got COVID-19 2 months ago.) had resolved.        The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Unknown) was unknown.   For SPIKEVAX NOS (SPIKEVAX NOS) (Unknown), the reporter did not provide any causality assessments.   It was unknown if the patient had received any other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant medication was reported. It was reported that the patient had COVID-19, 2 months ago. The patient had pills and she was okay now. The patient got a Moderna vaccination in the beginning. Doctor said the patient had a light case of corona. The patient took medication for 5 days.   Reporter did not allow further contact
the medical provider at the vaccination Center who prescreens and vaccinates their patients with vaccine that we provide them.  They request doses based on their prescreening and administer them. I keep them updated with all covid related information.  They send me names and DOB after vaccinating which I then document on in the online system.  I always look the names in the database and learned that the patient has 2 previous doses and should have gotten a bivalent booster instead of the medical provider listing it as his first.
Case number PHEH2014US022568, is an initial spontaneous report received from a physician on 08 Nov 2014. This report refers to a 13 year old patient of unknown age. The patient's medical history and concomitant medications were not reported. The patient was vaccinated with FLUCELVAX (batch number: Not reported) intramuscularly on 08 Nov 2014. No adverse events reported after the maladministration (inappropriate age at vaccine administration).
20 minutes after injection, I had left-sided head numbness with facial tingling. At 25 minutes post injection, I had a rush of heat, lip tingling, dry mouth and difficulty swallowing. The pharmacist gave me liquid Benadryl. I started to feel better. Day 3, I have lymph node swelling in my left armpit.
Systemic: Fainting / Unresponsive-Mild, Systemic: Shakiness-Mild, Additional Details: patient said she felt dizzy, and the pasted out.  Her boyfriend was with her, and helped me lay her on the floor. She Shook or seized for a few seconds and then came to.  She was confusion at first, but then recognized her boyfriend.  She asked him to call her Mom.  I talked to her Mom on the phone while she was starting to feel better.  We got her some water and a fan.  I had her wait an extra 30 minutes after she come to.
Pt, my daughter, ran a fever of 103 degrees for 2 days. I called the Dr and she said it was an adverse reaction and saw her.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 64-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 15Sep2022 at 13:00 as dose 5 (booster), single (Lot number: gj2524) at the age of 64 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, latency 12 days 13 hrs after the suspect product(s) administration, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: No known allergies. No other medication in 2 weeks. Paxlovid (treatment start date: 01Oct2022 and treatment stop date: 06Oct2022) for treatment of COVID-19.
a patient was given a dose of VARIVAX and approximately one week later, the patient was administered a dose of MMR II; No adverse effects were reported; This spontaneous report as received from a registered nurse, via company representative, regarding a child of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided.  On an unspecified date reported as Monday, the patient was vaccinated with varicella virus vaccine live (oka/merck)(VARIVAX) and approximately one week later, as the patient's mom was nervous that everyone was getting measles, the patient received a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II), both for prophyaxis (strength, dose, frequency, route, anatomical location, lot # and expiration date were not provided ).No adverse effects were reported. The reporter wanted to know which of the live vaccines became invalid and if what vaccine they need to repeat.
I did not have an adverse reaction to the vaccine. I tested positive for COVID-19 06/24/2022. I took two home test which where positive and I contacted my doctor and they prescribed Paxlovid. My symptoms where a scratchy throat, cough (more of an irritating cough), severe sinus infection. I never had a fever or body aches. After starting Paxlovid  I started feeling better. The sinus infection went away on 07/10.
Irregular menstrual cycle; Extreme abdominal cramping and pain; Absent period; This is a spontaneous report from a non-contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27May2021 at 12:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06May2021 at 12:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. On 11Jun2021 at 08:00, the patient experienced irregular menstrual cycle, extreme abdominal cramping and pain and absent period. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as result of events. The clinical outcome of the events irregular menstrual cycle, extreme abdominal cramping and pain, absent period was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient received vaccine left exam room, walked to check out window, states she is feeling well, becomes faint placed in chair becomes unresponsive and 2x shaking movements of upper body. Cold cloth applied to face and forehead, Ammonia salts given after approx 1-2 minutes Pt seems responsive Pt assisted to exam table rested approx 5 min states was feeling better.
This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 74-year-old female patient who received SHINGRIX (batch number ZY3X4, expiry date 30th April 2020). On 7th May 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 12th May 2018, 5 days after receiving SHINGRIX, the patient experienced shingles. In May 2018, the patient experienced injection site erythema and localized rash. On an unknown date, the outcome of the shingles, injection site erythema and localized rash were unknown. The reporter considered the shingles to be related to SHINGRIX. The reporter considered the injection site erythema to be probably related to SHINGRIX. It was unknown if the reporter considered the localized rash to be related to SHINGRIX. Additional details were provided as follows: At 14:15, the patient received the SHINGRIX vaccine in the right deltoid. The patient came into the pharmacy two days after reporting redness at the injection site of her right arm, approximately three inches across (latency less than a week after vaccination). On the reporting date, the patient came back to the pharmacy to report that she went to urgent care on Saturday, 12th May 2018, and was diagnosed with shingles. The shingles rash was on her right cheek and neck (latency less than a week after vaccination).
After second dose my arm hurt so much more than first dose; couldn't sleep well; today I've been nauseated; faint-like feeling; threw up twice; I have no appetite; stomach remains swollen; terrible tiredness; I am feeling bad; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 44 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 06Mar2021 (Batch/Lot number: unknown) at the age of 44 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Gastritis" (unspecified if ongoing). Concomitant medication(s) included: ESTRADIOL. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/lot number: Unknown, time 16:00, Anatomical Location: Arm Left), administration date: 13Feb2021, for COVID-19 immunization.  The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 06Mar2021, outcome "recovering", described as "After second dose my arm hurt so much more than first dose"; SLEEP DISORDER (non-serious) with onset 06Mar2021, outcome "recovering", described as "couldn't sleep well"; NAUSEA (non-serious) with onset 06Mar2021, outcome "recovering", described as "today I've been nauseated"; DIZZINESS (non-serious) with onset 06Mar2021, outcome "recovering", described as "faint-like feeling"; VOMITING (non-serious) with onset 06Mar2021, outcome "recovering", described as "threw up twice"; DECREASED APPETITE (non-serious) with onset 06Mar2021, outcome "recovering", described as "I have no appetite"; ABDOMINAL DISCOMFORT (non-serious) with onset 06Mar2021, outcome "recovering", described as "stomach remains swollen"; FATIGUE (non-serious) with onset 06Mar2021, outcome "recovering", described as "terrible tiredness"; FEELING ABNORMAL (non-serious) with onset 06Mar2021, outcome "recovering", described as "I am feeling bad". Therapeutic measures were taken as a result of pain in extremity, sleep disorder, nausea, dizziness, vomiting, decreased appetite, abdominal discomfort, fatigue, feeling abnormal.  Additional information: Patient not had allergies to medications, food, or other products. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received Estradiol within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. The arm does not get relieve regardless the patient took acetaminophen every 5 hours. The patient stated that the pain makes not caring to do of the patient day, she just wanted to feel better and that this passes away and she worried but her husband says she have to wait to get better. Since the vaccination, the patient not tested for COVID-19. The patient received treatment with Acetaminophen and Alka-Seltzer.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Immediate uncontrollable cough; loss of voice; irritation of throat; feeling of swelling of eyes, lips, tongue. Benadryl self-administered by me with no impact; nebulizer treatment with no relief; lasted 45 minutes in doctor's office; went home with slight reduction of symptoms; reaction continued at home for approximately 36 hours; took Benadryl and antihistimine intermittently with some relief.
Friday started to experience chest pain and shortness of breath. It progressively got worse. Went to urgent care the next day. Was told at urgent care it was costochondritis.  Never went away. Seen in ED in for worsening chest pain and hard to breathe. D-dimer was around 600. Chest x-ray was normal. Lymph nodes in chest were swollen according to the MD. ED MD advised her this was a result of the vaccine. Seen in follow up by CT ordered and result pending. labs redone. D-dimer now around 500.
I am a Type 2 Diabetic and had an increase in my blood sugar readings for about 2 weeks following getting the vaccine. With careful and healthy management my BS level was averaging 95 prior to getting the vaccine, and the day after the vaccine my BS level rose to 150 and stayed at an average of 140 for 13 days.
About 8 hours after the first shot at about 9am, I started feeling flu-like symptoms.   Had chills all night, called in sick, felt better by noon.   This time, I got the second done about 9am, started feeling flu-like symptoms around 4pm, by 9pm I had chills, sweats, raging headache, fever, nausea.  Spent the whole night dry-heaving, then slept until 1pm.   Haven't been able to eat anything but toast for the next 3 days.   Still have low grade nausea and fatigue, although it's improving slightly.
This case was reported by a pharmacist via call center representative and described the occurrence of abnormal touch sensation in a adult male patient who received FLUARIX QUADRIVALENT 2017-2018 season) (batch number C559A, expiry date 30th June 2018) for prophylaxis. On 25th September 2017, the patient received FLUARIX QUADRIVALENT 2017-2018 season. On an unknown date, less than a year after receiving FLUARIX QUADRIVALENT 2017-2018 season, the patient experienced abnormal touch sensation. On an unknown date, the outcome of the abnormal touch sensation was not recovered/not resolved. It was unknown if the reporter considered the abnormal touch sensation to be related to FLUARIX QUADRIVALENT 2017-2018 season. Additional details were provided as follows: The patient received FLUARIX QUADRIVALENT 2017-2018 season in the left deltoid, very close to his small pox scar. The patient had a sensation when a light touch was passed over the injection site that felt like a thorn under the skin. If pressed directly on the area, there was no pain. The pharmacist stated that the patient did not mention this until his current year's influenza vaccine came up. The pharmacist provided as much detail as was available. The pharmacist consented to be followed-up.
Almost immediately after receiving vaccine, child developed headache, school applied an icepack.  Mom states headache was severe, child had to hold her head, Mom gave her Melt Away tabs for headache.  On day 2, Tues, both mom and child's teacher began to notice behavior changes and child being off-task.  Could not sit & finish homework with mom.  On day 3 and 4, child received notes home from teacher that child was talkative & off-task.  No focus, distracted, & unable to complete work.  This behavior has continued & mom is having trouble knowing how to treat situation.  Child was sent to principal's office for first time ever recently.
pt recv vax & had high pitched crying, inconsolable x 4hr;began shortly p/vax;pt was well by time mom returned to urgent care;
It?s made my tinnitus louder too point can?t ignore disrupts sleep and made my neck tighter.